LifeX Ventures Research
Investment Thesis
LifeX Ventures (legal name Life Extension Ventures, founded 2022) invests at the intersection of AI and scientific advancement, betting that software, AI, and internet-native go-to-market motions will accelerate the adoption and commercialization of breakthroughs in the "two largest sectors on Earth: People and Planet." Concretely, that means health/biology on one side and climate/energy on the other, with artificial intelligence as the connective accelerant across both. The firm positions itself as bridging the "Valley of Death" for nascent, science-heavy companies, pairing capital with hands-on operating support for founders who are strong on science but need help with commercialization, GTM, and business-building.
Sector Focus
Two core pillars define the portfolio:
- Longevity, health, and biotech: cancer detection and diagnostics, surgical AI, ECG interpretation, immune-system platforms, obesity and preventive care, clinical data access, cell/gene therapy manufacturing automation, and life sciences research infrastructure.
- Climate and sustainability: home energy storage adoption, carbon/energy tax credit enablement, and related infrastructure.
A secondary, cross-cutting theme is AI/automation infrastructure that enables scientific and operational acceleration: lab robotics, warehouse automation, business process automation (procurement, finance, invoicing), and data/AI platforms (including some Web3-adjacent infrastructure).
Stage Focus
LifeX invests primarily at pre-seed and seed, occasionally following on into Series A for existing portfolio companies as they scale. Public trackers describe the firm as an active pre-seed/seed investor that also participates selectively in growth-stage rounds for the strongest performers in the portfolio.
Check Size
Exact check sizes are not publicly disclosed. Third-party trackers note that seed rounds the firm has participated in average roughly $5-6M in total round size, consistent with a syndicate/participant role rather than always leading. No explicit minimum or maximum check has been published on the firm's own site or in press coverage, so check size is treated as unknown for structured purposes.
Lead Tendency
Evidence is mixed and leans toward "follows/co-invests" rather than "leads." The firm's most recent large disclosed round (IMU Biosciences' Series A) was led by Molten Ventures with LifeX as a participating investor. Coverage of other portfolio raises (e.g., Trek Health) does not confirm a LifeX lead. Given the lack of confirmed lead credits, lead tendency is recorded as unknown/both rather than asserted as "leads."
Recent Activity
Portfolio companies have been active through 2025 and into 2026: Trek Health raised $11M for healthcare pricing transparency (April 2025); Function Health acquired full-body MRI provider Ezra (May 2025); Powerful Medical received FDA Breakthrough Device Designation for its cardiac AI ECG model (March 2025); Quibim received FDA clearance for a prostate lesion-detection imaging AI (March 2025); allO relaunched its redesigned restaurant-management platform (March 2025); and portfolio company Integral chaired a data-privacy panel at ISPOR 2025 (May 2025). IMU Biosciences, an immune-system AI platform LifeX backed in an earlier Series A alongside Molten Ventures, closed a large oversubscribed Series A extension in June 2026, though that specific extension round's investor list (IQ Capital, Molten Ventures, British Business Bank, Meltwind) does not explicitly re-confirm LifeX participation.
Portfolio Highlights
The current portfolio spans roughly 50 companies, heavily weighted toward healthcare/biotech (Function Health, Evaro, Quibim, Powerful Medical, Cure51, Betteromics, DashBio, Cromatic, Limula, Century Health, Hypervision Surgical, IMU Biosciences) with a smaller climate/energy cluster (Haven, Concentro AI) and an AI-infrastructure cluster (Zero Gravity, Kluster AI, Zylon, Silimate). Notable prior exits from the founders' earlier portfolios (pre-LifeX, via co-founders Amol Sarva and Inaki Berenguer individually) include Flywire (NASDAQ: FLYW), Marley Spoon (IPO), JUMP/Social Bicycles (acquired by Uber), and several acquisitions by Reddit, Datadog, Amazon, Palantir, Square, AstraZeneca/Boehringer Ingelheim, Instabase, Renault, Checkr, and New Relic — reflecting a founding team with a long individual track record even though LifeX itself is a younger fund (est. 2022).
Team
- Inaki Berenguer, PhD — Co-Founder. 3x entrepreneur/CEO (Pixable, acquired by SingTel for ~$30M; Contactive; CoverWallet, raised $60M, acquired by Aon in 2020). PhD and Master's from Cambridge, MBA from MIT. Former McKinsey and Microsoft Corporate Strategy.
- Amol Sarva, PhD — Co-Founder. 6x entrepreneur (co-founded Virgin Mobile USA, raised $550M, IPO 2007; Peek; Halo Neuroscience; Knotable; Knotel, raised $350M). BA Columbia, PhD Stanford (Cognitive Science). Former McKinsey; teaches at Columbia.
- Rika Christanto — Partner. 3x operator (COO at Idoven, raised $20M; co-founder/COO at Ontruck, raised $60M). BA and MBA from Harvard; former McKinsey consultant and Morgan Stanley technology banker.
- Yue Zhao — Venture Partner. CPO at Fuzzy Pet Health (raised $88M); early PM at Thumbtack. BS Berkeley, MBA Harvard; prior roles at Meta, McKinsey, and Cisco Corporate Strategy.
- Fabian Siegel — Venture Partner. 4x founder/CEO with one unicorn and two IPOs: ClickandBuy (CTO, raised $80M), Delivery Hero (co-CEO, raised $7.6B, IPO 2017), Marley Spoon (CEO, raised $240M, IPO 2018).
- Lisa Kleinsorge — Venture Partner. GTM leader; heads business development at Puzzle (B2B fintech). Prior roles at Twitter, Headspace, and Spotify; angel investor since 2018.
- Veeral Mehta, MD — Associate. Clinical Advisor/BD at Frontrow Health; BA Harvard, MD New York Medical College, MBA Columbia.
The firm also runs a fellows program staffing MBA/PhD candidates from Harvard, Stanford, and MIT into deal sourcing and diligence roles.
Decision Process
The presence of multiple partners and venture partners with distinct sourcing/diligence responsibilities, plus a fellows program feeding the pipeline, suggests a partnership-style decision process rather than a solo-GP model, though the exact investment-committee mechanics are not publicly documented.
Founder Preferences
LifeX explicitly targets founders building at the intersection of deep scientific/technical risk and AI-accelerated commercialization — often technical or clinical founders (MDs, PhDs, scientists) paired with operating chops, given the firm's stated role of supplying the commercialization support that science-first founders often lack.
Geographic Focus
Primary hubs are the SF Bay Area and New York City, with a portfolio that also reaches London, Switzerland, France, Austin, and Australia — a broadly US-centric but internationally flexible mandate, consistent with sourcing via a global fellows network.